Report
Valens Research

CL - Embedded Expectations Analysis - 2019 06 17

Colgate-Palmolive Company (CL:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) Earnings, with a 25.5x Uniform P/E, implying bullish expectations for the firm. However, management has concerns about their organic sales growth, their portfolio of products, and pricing and margins.

Specifically, they may lack confidence in their ability to drive market penetration in India, manage their gross margins, and sustain growth in organic sales, PCA, and Elta. Moreover, they may be concerned about pricing downsizing in the US, portfolio rebalancing efforts, and their ability to effectively advertise in Latin America. Also, they may lack confidence in the sustainability of Colgate Total consumption and their ability to drive increases in its sales velocity. Finally, management may be concerned about the impact of FX on European sales and their Asian turnaround strategy, and may be exaggerating the global penetration of their big brands and the incremental sales growth in their farm and feed channel.
Underlying
Colgate-Palmolive Company

Colgate-Palmolive manufactures and markets a variety of products in the United States and around the world. The company has two product segments: Oral, Personal and Home Care; and Pet Nutrition. Oral, Personal and Home Care products include toothpaste, toothbrushes and mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin care products, dishwashing detergents, fabric conditioners, household cleaners, and other similar items. Pet Nutrition products include specialty pet nutrition products manufactured and marketed by Hill's Pet Nutrition.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch